Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Veranova Fentanyl

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Fentanyl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,649Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Elysium Therapeutics Secures $7.5M To Advance Oral Fentanyl
    Elysium Therapeutics Secures $7.5M To Advance Oral Fentanyl

    28 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/elysium-therapeutics-raises-7-5-million-safe-round-to-accelerate-development-of-novel-rescue-therapy-designed-to-specifically-combat-oral-fentanyl-overdose-302671914.html

    PR NEWSWIRE
    28 Jan 2026
    Share Share
    CounterX Therapeutics Announce Publication Demonstrating CTRX-101
    CounterX Therapeutics Announce Publication Demonstrating CTRX-101

    29 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/counterx-therapeutics-announces-publication-demonstrating-ctrx-101-an-anti-fentanyl-monoclonal-antibody-therapy-reverses-fentanyl-induced-overdose-in-preclinical-model-302597828.html

    PR NEWSWIRE
    29 Oct 2025
    Share Share
    SUBLOCADE® Induction Shows Promise In Enhancing Opioid Use
    SUBLOCADE® Induction Shows Promise In Enhancing Opioid Use

    15 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/clinical-evidence-supports-rapid-sublocade-induction-as-a-strategy-to-improve-retention-in-opioid-use-disorder-treatment-302584003.html

    PR NEWSWIRE
    15 Oct 2025
    Share Share
    Study Explores Nalmefene Auto-Injector, Intranasal Naloxone
    Study Explores Nalmefene Auto-Injector, Intranasal Naloxone

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929817441/en/New-Study-Examines-Nalmefene-Auto-Injector-and-Intranasal-Naloxone-for-Reversal-of-Respiratory-Depression-Induced-by-Fentanyl-in-a-Controlled-Clinical-Study

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    Congress to Limit Marijuana Reschedule, but DEA Can Still Act Now
    Congress to Limit Marijuana Reschedule, but DEA Can Still Act Now

    24 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-24/congress-trying-to-limit-marijuana-rescheduling-but-dea-can-still-act-now

    PHARMAWEB
    24 Sep 2025
    Share Share
    Latin America: 4 More Argentinian Pharma Firms Shut Down
    Latin America: 4 More Argentinian Pharma Firms Shut Down

    16 Sep 2025

    // RAPS

    https://www.raps.org/news-and-articles/news-articles/2025/9/latin-america-roundup-four-more-argentinian-drugma

    RAPS
    16 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.